Precision BioSciences, Inc. (DTIL) News

Precision BioSciences, Inc. (DTIL): $10.64

-0.21 (-1.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DTIL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

Filter DTIL News Items

DTIL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DTIL News Highlights

  • 500 - Internal server error
  • Over the past 12 days, the trend for DTIL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about DTIL are VIVO and GENE.

Latest DTIL News From Around the Web

Below are the latest news stories about Precision Biosciences Inc that investors may wish to consider to help them evaluate DTIL as an investment opportunity.

Precision Bio's chief operating officer resigns

Precision BioSciences (DTIL) chief operating officer David Thomson, Ph.D., notified the Company of his resignation, effective July 2.The Company will reassign the duties of the COO to other members of the management and senior management team and use this opportunity to restructure the role in the organization.([[DTIL]] +3.8%)Previously (June 4):...

Seeking Alpha | June 7, 2021

Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma

Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced encouraging progress on two strategies designed to optimize the durability of allogeneic CAR T therapy in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). The Company reported updated interim results from its Phase 1/2a study of PBCAR0191, the Company’s investigational, off-t

Yahoo | June 4, 2021

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in Nature Communications that reports preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.

Yahoo | June 1, 2021

Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced the appointment of Alex Kelly as Chief Financial Officer. Alex joined Precision BioSciences in October 2020 as Chief Corporate Affairs Officer and has served as the company’s Interim Chief Financial Officer since December 2020. He will continue to serve as the company’s principal financial officer, reporting directly to Matt Kane, Chief Executive Officer and oversee the company’s finance, corporate communications, and investor relations functions. Shane Barton, the Company’s Vice President and Corporate Controller, has been serving as interim principal accounting officer and will now ...

Yahoo | May 27, 2021

Precision BioSciences to Participate in the Jefferies Virtual Healthcare Conference

Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and co-founder, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference being held from June 1-4, 2021.

Yahoo | May 26, 2021

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 32.65% and 86.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 13, 2021

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Yahoo | May 13, 2021

Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced it will publish first quarter 2021 financial results and provide a business update on Thursday, May 13, 2021.

Yahoo | May 6, 2021

Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS® genome editing platform for treatment of transthyretin amyloidosis (ATTR), will be presented at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, scheduled for May 11-14, 2021.

Yahoo | April 27, 2021

Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

Stanley R. Frankel, M.D. has been appointed to the Board of Directors for Precision BioSciences.

Yahoo | April 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5485 seconds.